Royalty Pharma (RPRX) Amortization - Intangibles (2019 - 2022)

Royalty Pharma has reported Amortization - Intangibles for 4 years, with the latest figure at $5.7 million in Q1 2022.

• Quarterly Amortization - Intangibles changed 0.02% year-over-year to $5.7 million in Q1 2022, while the trailing twelve-month figure through Dec 2022 was $5.7 million (down 75.34% YoY) and the FY2022 annual result came in at $5.7 million, down 75.34% from the prior year.
• Amortization - Intangibles retreated to $5.7 million in Q1 2022 per RPRX's latest filing, from $5.8 million in the prior quarter.
• Over five years, Amortization - Intangibles peaked at $5.8 million in Q3 2019 and troughed at $5.7 million in Q1 2022.
• A 4-year average of $5.8 million and a median of $5.8 million in 2019 frame the typical range for Amortization - Intangibles.
• The sharpest annual moves came in 2020 and 2021: Amortization - Intangibles changed 0.0% in 2020, then slipped 1.08% in 2021.
• Over 4 years, Amortization - Intangibles stood at $5.8 million in 2019, then changed by 0.0% to $5.8 million in 2020, then changed by 0.0% to $5.8 million in 2021, then declined by 2.17% to $5.7 million in 2022.
• According to Business Quant data, Amortization - Intangibles over the past three periods registered $5.7 million, $5.8 million, and $5.8 million for Q1 2022, Q4 2021, and Q3 2021 respectively.